ODI Pharma AB publ announced earnings results for the fourth quarter ended June 30, 2020. For the fourth quarter, the company announced operating loss was SEK 1.227 million compared to SEK 1.473 million a year ago. Net loss was SEK 1.232 million compared to SEK 1.759 million a year ago. Basic loss per share was SEK 0.08. Basic loss per share from continuing operations was SEK 0.08. For the full year, operating loss was SEK 4.934 million compared to SEK 3.341 million a year ago. Net loss was SEK 4.962 million compared to SEK 3.632 million a year ago. Basic loss per share was SEK 0.5. Basic loss per share from continuing operations was SEK 0.5.